Raymond James Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $70.00
Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective cut by Raymond James from $92.00 to $70.00 in a report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on CYTK. Mizuho reduced their price target on shares […]
More Stories
Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Aviso Wealth Management
Aviso Wealth Management grew its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 16.7% in the 3rd...
Jackson Hill Advisors LLC Cuts Stock Holdings in Alphabet Inc. (NASDAQ:GOOG)
Jackson Hill Advisors LLC lowered its position in Alphabet Inc. (NASDAQ:GOOG – Free Report) by 53.6% in the 3rd quarter,...
Capital City Trust Co. FL Acquires 1,631 Shares of Walmart Inc. (NYSE:WMT)
Capital City Trust Co. FL increased its holdings in shares of Walmart Inc. (NYSE:WMT – Free Report) by 2.0% in...
Cassaday & Co Wealth Management LLC Buys 748 Shares of Walmart Inc. (NYSE:WMT)
Cassaday & Co Wealth Management LLC raised its holdings in Walmart Inc. (NYSE:WMT – Free Report) by 3.0% during the...
Taurus Asset Management LLC Trims Stake in Bank of America Co. (NYSE:BAC)
Taurus Asset Management LLC lessened its position in Bank of America Co. (NYSE:BAC) by 4.6% in the third quarter, according...
OneAscent Wealth Management LLC Takes $647,000 Position in The Procter & Gamble Company (NYSE:PG)
OneAscent Wealth Management LLC purchased a new position in The Procter & Gamble Company (NYSE:PG – Free Report) during the...